BridgeBio Pharma Inc. (BBIO)
BBIO trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1743881/000174388126000009/0001743881-26-000009-index.htm. Net income: SEC 10-K (us-gaap:ProfitLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | BBIO on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2019 |
| SEC CIK | 0001743881 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $502.1M |
| Net income | -$732.9M |
| Operating income | -$523.4M |
| Net margin | -146.0% |
| Operating margin | -104.2% |
| Revenue growth | +126.3% |
| Cash | $570.1M |
| Total assets | $936.0M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 30.0× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-10-29 |
| Cash and burn | $1.5B cash; operating cash flow -$92.2M a quarter. | Report 2026-09-30 |
| Shares outstanding | 194,800,782 (2026-10-22); 192,708,813 a year earlier; 173,967,052 three years earlier. | Cover page 2026-10-22 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 2 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2026-07-24 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Deloitte & Touche LLP, San Francisco, California, United States | PCAOB Form AP 2026-02-27 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $117.8M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $353.2M | -$56.7M | -$44.2M | $1.5B | $2.6B | $945.5M | 10-Q 2026-10-29 |
| Q2 2026 2026-06-30 | $243.7M | -$155.9M | -$71.1M | $677.9M | $2.7B | $713.1M | 10-Q 2026-08-10 |
| Q1 2026 2026-03-31 | $194.5M | -$166.6M | -$197.3M | $879.9M | $2.7B | $580.0M | 10-Q 2026-05-07 |
| Q4 2025 2025-12-31 | $154.2M | -$194.6M | -$56.4M | $570.1M | $2.0B | $502.1M | 10-K 2026-02-24 |
| Q3 2025 2025-09-30 | $120.7M | -$182.7M | -$109.6M | $643.0M | $2.0B | $353.8M | 10-Q 2026-10-29 |
| Q2 2025 2025-06-30 | $110.6M | -$183.8M | -$80.7M | $749.0M | $0 | $235.8M | 10-Q 2026-08-10 |
| Q1 2025 2025-03-31 | $116.6M | -$169.6M | -$199.2M | $540.6M | $0 | $127.4M | 10-Q 2026-05-07 |
| Q4 2024 2024-12-31 | $5.9M | -$267.4M | -$195.3M | $681.1M | $437.3M | $221.9M | 10-K 2026-02-24 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B7 | 2026-08-14 |
| Latest annual report | 10-K | 2026-02-24 |
| Latest quarterly / interim | 10-Q | 2026-10-29 |
| Latest current report | 8-K | 2026-10-29 |
| Latest proxy | DEFA14A | 2026-04-24 |
Source: SEC EDGAR submissions feed, 834 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +5.4% |
| 1 month | +23.7% |
| 3 months | -3.6% |
| Year to date | +2.4% |
| 1 year | +20.4% |
| From 52-week high | -13.2% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| JAZZ | Jazz Pharmaceuticals plc Common Stock (Ireland) | $239.77 | -0.74% | $15.4B |
| ELAN | Elanco Animal Health Incorporated | $26.41 | -1.38% | $13.2B |
| ASND | Ascendis Pharma A/S Ordinary Share | $271.73 | -1.33% | $17.9B |
| RDY | Dr. Reddy's Laboratories Ltd | $14.70 | -0.27% | $12.3B |
| BMRN | BioMarin Pharmaceutical Inc. | $57.99 | +1.33% | $11.2B |
| ALNY | Alnylam Pharmaceuticals Inc. | $159.73 | -3.22% | $21.4B |
| MDGL | Madrigal Pharmaceuticals Inc. | $423.96 | -0.80% | $9.8B |
| VTRS | Viatris Inc. | $20.74 | -0.38% | $23.8B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier